Edition:
United States

Ironwood Pharmaceuticals Inc (IRWD.OQ)

IRWD.OQ on NASDAQ Stock Exchange Global Select Market

17.05USD
12:04pm EDT
Change (% chg)

$-0.04 (-0.23%)
Prev Close
$17.09
Open
$17.16
Day's High
$17.29
Day's Low
$16.83
Volume
85,706
Avg. Vol
359,032
52-wk High
$21.19
52-wk Low
$13.00

Chart for

About

Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease... (more)

Overall

Beta: 0.79
Market Cap(Mil.): $2,617.46
Shares Outstanding(Mil.): 153.16
Dividend: --
Yield (%): --

Financials

  IRWD.OQ Industry Sector
P/E (TTM): -- 103.50 32.14
EPS (TTM): -0.75 -- --
ROI: -19.63 1.52 12.66
ROE: -- 0.25 14.84

BRIEF-Ironwood Pharma Sends Letter To Shareholders Highlighting Director Nominees

* IRONWOOD PHARMACEUTICALS SENDS LETTER TO SHAREHOLDERS HIGHLIGHTING DIRECTOR NOMINEES

May 14 2018

BRIEF-Ironwood And Allergan Announce Settlement With Aurobindo Pharma Resolving Linzess Patent Litigation

* IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH AUROBINDO PHARMA RESOLVING LINZESS (LINACLOTIDE) PATENT LITIGATION

May 03 2018

BRIEF-Ironwood Pharmaceuticals To Separate Into Two Independent, Publicly Traded Companies

* IRONWOOD PHARMACEUTICALS ANNOUNCES INTENT TO SEPARATE SOLUBLE GUANYLATE CYCLASE (SGC) BUSINESS FROM COMMERCIAL AND GASTROINTESTINAL BUSINESS

May 01 2018

BRIEF-Ironwood Pharmaceuticals Reports Q1 Loss Per Share Of $0.29

* IRONWOOD PHARMACEUTICALS PROVIDES FIRST QUARTER 2018 INVESTOR UPDATE

May 01 2018

BRIEF-Ironwood Announces Director Nomination From Sarissa Capital

* RECEIVED NOTICE FROM SARISSA CAPITAL MANAGEMENT LP OF INTENTION TO NOMINATE ALEX DENNER TO STAND FOR ELECTION Source text for Eikon: Further company coverage:

Apr 09 2018

Earnings vs. Estimates